63 LC-MS/MS-method development quantifying FVIII REFERENCES 1. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998; 92: 3983-3996. 2. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol. 1998; 59: 288-294. 3. Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program. 2010; 2010: 191-196. 4. Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005; 80: 55-63. 5. Jaffray J, Young G, Ko RH. The bleeding newborn: A review of presentation, diagnosis, and management. Semin Fetal Neonatal Med. 2016; 21: 44-49. 6. Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017; 92: 695-705. 7. Mingot-Castellano ME, Nunez R, Rodriguez-Martorell FJ. Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc). 2017; 148: 314-322. 8. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol. 2001; 5: 389-404; quiz following 431. 9. National Hemophilia Foundation. Hemophilia A, 2017. https://www.hemophilia.org/Bleeding-Disorders/ Types-of-Bleeding-Disorders/Hemophilia-A. Accessed on 02-05-2019. 10. Bjorkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM, Advate Clinical Program G, Collins PW. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010; 8: 730-736. 11. Moser KA, Adcock Funk DM. Chromogenic factor VIII activity assay. Am J Hematol. 2014; 89: 781-784. 12. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost. 2002; 28: 247-256. 13. Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost. 2000; 84: 942-948. 14. Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003; 120: 34-39. 15. Duncan E, Rodgers S. One-Stage Factor VIII Assays. Methods Mol Biol. 2017; 1646: 247-263. 16. Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015; 94: 38-44. 17. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med. 1953; 41: 637-647. 18. Over J. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl. 1984; 41: 13-24. 19. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie. 2010; 30: 207-211. 3
RkJQdWJsaXNoZXIy MTk4NDMw